{
  "ticker": "IBX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02976454",
  "id": "02976454",
  "pages": 5,
  "price_sensitive": false,
  "date": "20250804",
  "time": "0935",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250804/pdf/06mhk5ldxqk91k.pdf",
  "summary": "**Capital Raising Announcement (Placement):**  \n- **Structure:** Placement  \n- **Total securities issued:** 45,000,000 ordinary shares (ASX: IBX)  \n- **Issue price:** AUD 0.015 per share  \n- **Proposed issue date:** 6 August 2025  \n- **Use of proceeds:** Advance MagSense\u00ae HER2 Breast Cancer tech and initiate Phase 1 trials for prostate/ovarian cancer.  \n- **Broker:** CPS Capital Group Pty Ltd (fees: 2% management + 4% capital raising fee, payable in cash or shares).  \n- **Approval:** 25.3M shares issued under 15% placement capacity; 19.7M under 10% capacity (no shareholder approval).  \n\n**Key Points:**  \n- No underwriting or escrow restrictions.  \n- Rationale for placement over SPP/entitlement offer: Speed, cost efficiency, and broader investor access.",
  "usage": {
    "prompt_tokens": 1932,
    "completion_tokens": 203,
    "total_tokens": 2135,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-03T23:55:47.866603"
}